Merck beats Q3 estimates, lifts full-year outlook; Keytruda sales top forecasts

Merck reported Q3 adjusted EPS of $2.49, beating the $2.09 consensus, on revenue of $18.09 billion. Keytruda and Qlex combined for $8.6 billion in sales. Winrevair also beat at $694 million. Full-year guidance raised: EPS $2.77-$2.82, revenue $66.8-$67.3 billion. Shares eased fractionally. The results come after a leak of cancer vaccine data with Moderna caused a prior selloff.